Clearwater Analytics Finalizes Acquisition of Enfusion
Clearwater Will Deliver Industry’s First Unified, Cloud-Native Front-to-Back Platform for Institutional Investors
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced the successful completion of its acquisition of Enfusion, Inc. (NYSE: ENFN), a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund sectors, in a deal valued at approximately $1.5 billion.
This strategic combination positions Clearwater as the industry’s first single-instance, multi-tenant, cloud-native platform to unify front, middle, and back-office investment operations. By integrating portfolio and order management, IBOR, risk, accounting, and client reporting into one seamless solution, Clearwater is replacing the fragmented legacy model with a modern platform that empowers faster decision-making and operational clarity across asset classes and geographies.
“The close of the Enfusion acquisition marks a major milestone—not just for Clearwater, but for the entire investment management industry,” said Sandeep Sahai, Chief Executive Officer of Clearwater Analytics. “By combining Enfusion’s strong front-office capabilities with our established middle and back-office solutions, we are accelerating our journey towards a fully integrated, cloud-native front-to-back investment management platform. This combination will eliminate costly data handoffs and inefficiencies stemming from fragmented workflows, empowering our clients to make faster, data-driven decisions with complete confidence in their data.”
“I’m immensely proud of what the Enfusion team has achieved and the shareholder value we delivered. Enfusion's focus on innovation and client requirements created a world-class disruptive technology platform, fundamentally changing how our clients execute their operational workflows, implement investment strategies, manage portfolios, and optimize data insights,” said Oleg Movchan, former CEO of Enfusion. “By joining forces with Clearwater, we’re opening up amazing possibilities for the next wave of innovation in investment technology. I couldn't be more optimistic about how this combination will benefit our clients and transform the industry.”
Today’s institutional investors—asset managers, insurers, pensions, endowments, and sovereign funds—face increasing complexity across portfolios, geographies, and asset classes. Many still rely on outdated systems that silo data and delay insight. The expanded Clearwater platform will address these challenges by offering:
- Seamless integration across front, middle, and back-office workflows
- A single security master and data model for consistent, real-time views of positions, performance, and risk
- An open architecture that connects to a growing ecosystem of partners and capabilities
“Enfusion adds proven front-office depth to the Clearwater platform, giving our clients real-time access to portfolio and order management, IBOR, risk, and reporting—all in one system,” said Neal Pawar, President, Head of Asset Management at Clearwater Analytics and former Chief Operating Officer at Enfusion. “The operational benefits are immediate: no batch processing, no manual reconciliation, and no duplication of data. Clients now have a shared, live view of their portfolios and operations—enabling faster execution, stronger risk oversight, and a platform that evolves with them. This is the new foundation for institutional investment technology and operations.”
Clearwater’s growth in asset management—its largest market segment—is expected to accelerate, with Enfusion’s strength in the hedge fund space and the ability to integrate Enfusion’s front office capabilities with Clearwater’s middle and back office. This will result in a meaningful expansion of Clearwater’s Total Addressable Market.
The acquisition also significantly expands Clearwater’s international presence. Enfusion generates 38% of its revenue from Europe and Asia, supported by strong teams in London, Mumbai, Bangalore, Singapore, and Hong Kong. Clearwater will now serve clients from key global hubs including Boise, New York, Edinburgh, and New Delhi, providing localized support and delivery at scale.
Unified client onboarding can currently be offered, and the first wave of integration milestones—including unified dashboards, streamlined reconciliation, and roadmap alignment is already well underway.
This announcement follows Clearwater’s recent acquisition of Blackstone’s BISTRO platform, which adds deep analytics and data infrastructure for private and structured credit markets. Clearwater also previously announced its intent to acquire Beacon, a provider of enterprise risk analytics and technology infrastructure. That transaction is expected to close in the coming weeks, further enhancing Clearwater’s ability to support complex, cross-asset strategies with institutional-grade analytics.
Clearwater Analytics will discuss the Enfusion acquisition during its First Quarter 2025 earnings conference call on April 30, 2025, at 5:00 p.m. ET. Registration for the live webcast and a copy of an investor presentation deck regarding the acquisition is available on the Company’s investor relations website.
Advisors
J.P. Morgan Securities LLC served as financial advisor to Clearwater Analytics, and JPMorgan Chase Bank, N.A., provided committed financing for the transaction. Kirkland & Ellis LLP served as legal advisor to Clearwater Analytics. Goldman, Sachs & Co. LLC served as exclusive financial advisor to Enfusion’s Special Committee. Dechert LLP served as legal advisor to the Special Committee, and Goodwin Procter LLP served as legal counsel to Enfusion.
About Clearwater Analytics
Clearwater Analytics (NYSE: CWAN) is transforming investment management with the industry's most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, Clearwater's single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, Clearwater supports over $8.8 trillion in assets globally. Learn more at www.clearwateranalytics.com.
About Enfusion, a Clearwater Analytics company
Enfusion, a Clearwater Analytics company, provides the front-office technology foundation that powers modern investment operations for hedge funds and asset managers. The platform delivers real-time portfolio and order management, IBOR, risk analytics, and comprehensive reporting in one system—eliminating traditional operational barriers. By removing batch processing, manual reconciliation, and data duplication, Enfusion enables faster execution and stronger risk oversight across global portfolios. As part of Clearwater, Enfusion supports the industry's most advanced front-to-back investment management solution. Learn more at www.enfusion.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the beliefs and assumptions of Clearwater’s management and on information currently available to them. Forward-looking statements include information concerning the following factors in reference to Clearwater and/or Enfusion: possible or assumed future results of operations, possible or assumed performance, business strategies, technology developments, financing and investment plans, competitive position, industry, economic and regulatory environment, potential growth opportunities and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” or similar expressions and the negatives of those terms, but are not the exclusive means of identifying such statements.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond Clearwater’s control, that may cause their actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, Clearwater’s ability to successfully integrate the operations and technology of Enfusion with those of Clearwater and to obtain third party data rights, retain and incentivize the employees of Enfusion following the close of the acquisition, retain Enfusion’s clients, repay debt to be incurred in connection with the Enfusion acquisition and meet financial covenants to be imposed in connection with such debt, risks that cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected, risks and uncertainties similar to the foregoing with respect to Clearwater’s previously announced acquisitions of Beacon and Bistro, as well as other risks and uncertainties discussed under “Risk Factors” in Clearwater’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the US Securities and Exchange Commission (the “SEC”) on February 26, 2025 (as amended by Amendment No. 1 thereto, filed with the SEC on March 7, 2025) and in Enfusion’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 3, 2025, as well as in other periodic reports filed by Clearwater and Enfusion with the SEC. These filings are available at www.sec.gov and on Clearwater’s website, investors.clearwateranalytics.com. Given these uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing Clearwater’s expectations or beliefs as of any date subsequent to the time they are made. Clearwater does not undertake to and specifically declines any obligation to update any forward-looking statements that may be made from time to time by or on behalf of Clearwater.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421999466/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 15:00:00 CET | Press release
Presentation Ceremony to Take Place in Tokyo in April The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication
Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 14:31:00 CET | Press release
With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will
Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 14:00:00 CET | Press release
Lucend Seed round led by Remarkable Ventures Climate (RVC) to bring Transparent AI insights to data center operators in the U.S. increasing operational efficiency by 40% Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise env
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 14:00:00 CET | Press release
Study could lead to first-ever topical steroid-free treatment for the inner eye disease non-infectious anterior uveitis (NIAU) The study builds on ocular pharmacokinetic models demonstrating delivery after topical application and on animal models of experimental uveitis demonstrating pharmacological effects Novaliq is expanding with this proof-of-concept study into retina and inner-eye diseases as targeted topical delivery of EyeSol®-based drugs allowing to develop breakthrough therapies Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Pha
IQM Quantum Computers Appoints Jan Goetz as Sole CEO to Lead Next Phase of Global Growth26.1.2026 10:15:00 CET | Press release
Jan Goetz becomes sole CEO, while Søren Hein is appointed Chief Operating Officer and Deputy CEO. Former Co-CEO Mikko Välimäki transitions out of his commercial role and remains as an advisor until 31 March 2026. This new leadership structure is designed to strengthen IQM's global strategic direction, planning and execution. IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, today announced a transition from its Co-CEO structure to a single Chief Executive Officer model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126737805/en/ From left to right: Jan Goetz (Co-founder & CEO) and Søren Hein (Chief Operating Officer and Deputy CEO) Co-founder and current Co-CEO Dr Jan Goetz becomes sole CEO effective since January 1st, following a resolution passed by the IQM board. In addition, Dr Søren Hein has been appointed Chief Operating Officer and Deputy CEO. As part of the transition, Mikko
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom